Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy | Zendy

Marco Roffi | Zendy; Derek P. Chew | Zendy; Debabrata Mukherjee | Zendy; Deepak L. Bhatt | Zendy; Jennifer White | Zendy; David J. Moliterno | Zendy; Christopher Heeschen | Zendy; Christian W. Hamm | Zendy; Mark Robbins | Zendy; Neal S. Kleiman | Zendy; Pierre Théroux | Zendy; Harvey D. White | Zendy; Eric J. Topol | Zendy

Open Access

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy

Author(s) -

Marco Roffi,

Derek P. Chew,

Debabrata Mukherjee,

Deepak L. Bhatt,

Jennifer White,

David J. Moliterno,

Christopher Heeschen,

Christian W. Hamm,

Mark Robbins,

Neal S. Kleiman,

Pierre Théroux,

Harvey D. White,

Eric J. Topol

Publication year - 2002

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.2002.3160

Subject(s) - medicine , odds ratio , percutaneous coronary intervention , myocardial infarction , revascularization , cardiology , unstable angina , acute coronary syndrome , abciximab , eptifibatide , tirofiban , randomized controlled trial , discontinuation , surgery

To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research